THE TAPE

Thermo Fisher Scientific, Inc.

$691.33▼ −1.27%
Last close
Relative strength
87RS
of 99, against every stock▲ +1 on the month
Powering up
Unconfirmed
+56.1%
six months against the S&P 500
52-week range
−5.0%
from the high
$435.27$727.56
Setup
blue skyclimbing
+6.8%
against the pivot at $647.00
No report date on the calendar.
Growth FLATProof SHOWN
Quarter to Sep 26, revenue +9% on a year ago
11/16 O 699.08 H 701.51 L 687.92 Vol 1.6M
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

All four are in order, fastest above slowest — every timeframe pointing the same way.

RS87
vs pivot+6.85%
Tightening1.12×
Dry-up0.77×
Up/down vol0.21
From high5%
climbing7 of 9checks
Previous breakout trailed out ▼ −3.12% in Jan
Powering up
Support and resistance
Support below
$664.62
-3.9% · tested 4× · last 6 sessions ago
Resistance above
$701.37
+1.5% · tested 3× · last 18 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 3.0 weeks and fell 8% from its ceiling at its deepest. The pivot is $647.00, and the stock closed 6.8% above that pivot. Its relative strength rating is 87.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against the S&P 500
+3.4%
Three months against the S&P 500
+21.7%
Six months against the S&P 500
+56.1%

Its industry has too few members to make an index of, so it is read against the S&P 500 and can only be turning, caution or unconfirmed.

Also on
Peers
Catalyst roadmap
29
days
Ex-dividend in 29 days
Dec 15, 2026
  1. Ex-dividendconfirmedin 29d
    Ex-dividend date
    Dec 15, 2026
How it moves on earnings

On average 5.5% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$47.4B
+9.1% year on year
Operating margin
17.9%
Net margin
15.0%
Free cash flow
$7.6B
3.0% of market cap
Price to sales
5.40×
Price to earnings
36.1×

Twelve months to Sep 26, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Oct 21
Key takeaway
Profitable and cash generating; the question is growth.
Revenue
$12.1B
+1.2% QoQ · +9.1% YoY
Gross margin
—
Net income
$1.7B
Positive
Free cash flow
$2.1B
Cash generating

What the numbers say

  • Revenue +9.1% year over year, +1.2% on the quarter
  • Good: Profitable: net income $1.72B, operating margin 18.6%
  • Good: Cash generating: operating cash flow $2.55B, free cash flow $2.11B
  • Weak: Net debt $37.91B · cash $5.46B
Revenue by quarter
Free cash flow
Net income
shares -1.9% in a year · net debt $37.9B

What is not obvious

  • Contracted backlog (remaining performance obligations) $29.87B, 0.6× trailing revenue, +1% on the quarter. Backlog is not recognised revenue
Final read
Growth: FLAT · Economic proof: SHOWN
Key question: Can the cash generation hold as growth slows?
The next test is the balance sheet: net debt $37.91B · cash $5.46B.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 8 of 46 tracked funds at the end of Q3 2026.

Last quarter: 3 bought new, 5 added.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
A director or officer changedFiling · 2026-10-31
5.02
No measurable effect: stocks behave like random ones over the next three sessions (1,288 cases over 54 nights).
Reported resultsFiling · 2026-10-22
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Earnings comingEvent · 2026-10-20
reports 2026-10-21 bmo
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
Unusual volumeTape · 2026-09-19
3.9 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
New 52-week highTape · 2026-09-18
2.4x vol
Mixed: stocks have lagged random stocks by 0.9% over three sessions, not consistently enough to call (554 cases over 52 nights). Against their own sector they have lagged by 2.1%.
Unusual volumeTape · 2026-09-18
4.5 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Unusual volumeTape · 2026-09-16
3.1 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
92
$66,115,338 total

Sold: Pettiti Gianluca, Britt Lisa P., CASPER MARC N, Shafer Michael D, Holmes Joseph R..

Not counted above: 39 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-13 Pettiti Gianluca · President & COOsell400$280,568
2026-11-13 Pettiti Gianluca · President & COOoption exercise3,733$1,155,849
2026-11-13 Pettiti Gianluca · President & COOsell3,733$2,618,401
2026-10-28 SPERLING SCOTT M · Directorgift3,490
2026-10-28 Britt Lisa P. · Sr. VP and Chief HR Officersell2,831$1,999,960
2026-08-31 Pettiti Gianluca · President & COOsell400$245,752
2026-08-31 Pettiti Gianluca · President & COOoption exercise3,733$1,155,849
2026-08-31 Pettiti Gianluca · President & COOsell3,733$2,293,481

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

The geometry
Level · ceiling$727.56
Wrong below$656.24
Measured target · a squeeze has no height to projectnone
Through to the apex76%
Leaning · and easingup
Length1.6 weeks

Leaning is where price has been sitting against its own range while the range was quiet. It is not a forecast of which way the range opens up, and this site has no measurement that would support one.

What lines up

7 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy3
Buy20
Hold3
Sell0
Strong sell1

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

Checking your subscription…

X-ray
3w · 8%

The most recent of 2 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Thermo Fisher Scientific, Inc. (TMO) — The Tape